{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hse.00785:a retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Ahse.00785%3Aa",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.003797,
    "timestamp_received": "2026-04-24T01:51:36.741565+00:00Z",
    "timestamp_returned": "2026-04-24T01:51:36.745362+00:00Z",
    "trace_id": "1e9ce580-218b-4704-8fb1-f1e1c68e83b2"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-04-09"
  },
  "data": [
    {
      "id": "ind:hse.00785:a",
      "indication": "Pertuzumab/ trastuzumab (Phesgo) for the maintenance treatment of adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment.",
      "initial_approval_date": "2022-12-20",
      "initial_approval_url": null,
      "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab / trastuzumab (phesgo) for reimbursement as a treatment option for the maintenance treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment. The regime further states that patients should have already been treated with pertuzumab and trastuzumab in combination with DOCEtaxel, PACLItaxel, or vinorelbine.",
      "raw_biomarkers": null,
      "raw_cancer_type": "Breast cancer",
      "raw_therapeutics": "Pertuzumab / trastuzumab (phesgo)",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:hse.00785",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Pertuzumab/Trastuzumab (Phesgo) Maintenance Therapy. NCCP National SACT Regimen. HSE.",
        "title": null,
        "aliases": [],
        "description": "Pertuzumab/Trastuzumab (Phesgo) Maintenance Therapy, 2024, version number 3, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6659/785_v3_Pertuzumab_trastuzumab_Phesgo.pdf",
        "urls": [
          "https://healthservice.hse.ie/documents/6659/785_v3_Pertuzumab_trastuzumab_Phesgo.pdf"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "hse",
              "type": "Agent",
              "agentType": "organization",
              "name": "Health Service Executive",
              "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-10-01",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://healthservice.hse.ie/staff/information-healthcare-workers/nccp/national-sact-regimens/",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": null,
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": null,
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": null,
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2023-08-10",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}